"Amikacin, Ingredient in Arikace is FDA approved antibiotic for CF. But it wasn't delivered well in lung.Insmed's Liposome technology solves this delivery problem by placing amikacin into a liposome, which allows an extention duration of drug efficacy. Amikacin efficacy suggests that the drug is potentially better than TOBI which brings in annual revenues around $400m.With a market cap near $295M, Insmed appears to be undervalued by at least $100M, if not more.
As of this morning, Lazard Capital has started its coverage of Insmed with a "buy" rating and a 1 year target of $21 a share." As of late 2013,
Scott Matusow indicated he was long INSM at that time.
Lazard has increased their PT to $24 and then to $28.
Canaccord has increased their PT from $18 to $30 in this time frame.
Leerink Swann went from $12 to $22 in this time frame.